We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
Olá - Rio is calling!
Save the date for our PVRI 2025 Congress, which will be held in Rio de Janeiro, Brazil, from Wednesday 29 January - Sunday 2 February 2025.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
Members are invited to nominate a proactive PVRI member with a high-profile scientific reputation in the fields of PH and PVD to serve as PVRI President 2026/2027. If you are not a current member, please renew your membership first. Nominations are open until the end of August 2024.
Webinar presentations: Autoantibodies as the cause of pulmonary arterial hypertension, Pulmonary hypertension in myelodysplastic syndrome, Prevalence and effect of myelofibrosis on pulmonary arterial hypertension, Mast cells as the cause of pulmonary vascular remodeling in pulmonary arterial hypertension, B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary hypertension, Emergency myelopoiesis contributes to immune cell exhaustion in pulmonary vascular remodeling
Ladakh, a land of spirituality with mystic Lamas and a traveller’s paradise with mighty mountains and high passes with their splendid beauty, welcomes you to the 7th International Leh Symposium 2024 with a theme on ‘Molecular mechanisms and therapeutics of hypoxic lung’.
Organised by the leaders of the PVRI LATAM Task Force, the meeting will address the latest advances in diagnosis and management of adult and paediatric PH and explore avenues to increase the partnership of adult and paediatric physicians to improve clinical outcomes and quality of life for PH patients across the entire lifespan.
Webinar presentations: Autophagy and BMPR2 receptor degradation as the cause of PAH; BMPR1A promotes ID2-ZEB1 interaction to suppress endothelial to mesenchymal transition in PAH; Cardiovascular and pulmonary phenotypes for single and double knockout mice deficient in BMP9 and BMP10; BMPR2 – When and where the animal models match patient disease; miR-182 balances BMP and TGF signaling pathways to regulate PH
Webinar presentations: Therapeutic efficacy and mechanisms of Drpitor1a in PAH; SNPs for sirtuin3 and uncoupling protein2 are causal of PAH and diabetes disease severity; Mitochondrial control of metabolic, angiogenic, and hematopoietic function in PH onset and progression; Heteroplasmy of wild-type mitochondrial DNA variants causes metabolic heart disease with PH.
Pollution and climate change constitute a combined, grave and pervasive threat to humans and to the life-support systems on which they depend. Evidence shows a strong...
A 56-year-old male patient was admitted to our hospital with respiratory distress persisting for half a month as the chief complaint. The patient developed dyspnea following a heated argument...
We are delighted to invite our members to nominate a proactive PVRI member with a high-profile scientific reputation in the fields of PH and PVD to serve as PVRI President 2026/2027. If you are not a current member of PVRI, you’ll need to sign up first to access the nomination form. For more information, please read the President's Terms of Reference and Recruitment Process. Nominations are open until the end of August 2024.
The announcement that many of you have been waiting for...drumroll please...our PVRI 2025 Congress will be held in Rio de Janeiro, Brazil, from Wednesday, 29 January, to Sunday, 2 February 2025. Save the date!
Cereno Scientific, a pioneering biotech developing innovative treatments for rare and common cardiovascular diseases, has joined PVRI as a Roundtable member.
The Burke Advanced Fellowship in Pulmonary Heart Disease at The Brigham and Women’s Hospital and Harvard Medical School invites applications for an advanced fellowship in pulmonary heart disease starting 1 July 2025.